Aurora Cannabis Inc. (ACB) and Vectura Fertin Pharma, Inc., a leading innovator in wellness and healthcare, have announced the launch of their newly developed Luo CBD lozenge. This marks a significant milestone in their ongoing collaboration, bringing Vectura Fertin Pharma’s first medical cannabis CBD lozenge to the Canadian market.
The product, developed by Vectura Fertin Pharma, is a novel dissolvable lozenge designed for easy dosing. It is manufactured and packaged by Cogent International, a subsidiary of Vectura Fertin Pharma, which leverages Aurora’s extensive Canadian medical cannabis patient platform. This partnership allows Cogent to access valuable patient feedback, enabling them to refine the product proposition and gather real-world data for future innovations.
“As the leading provider of medical cannabis in Canada, the launch of the newly developed Luo CBD lozenge on our platform is a significant and exciting milestone at the beginning of our strategic collaboration with Vectura Fertin Pharma,” stated Aurora CEO Miguel Martin. “We are committed to bringing innovative solutions to patients and this launch reinforces our position at the forefront of Canada’s medical cannabis industry.”
This launch is just the beginning of the partnership between Aurora and Vectura Fertin Pharma. Both companies are exploring opportunities to expand their collaboration, potentially bringing other Vectura Fertin Pharma medical cannabis products to the Canadian market.
Following this announcement, Aurora’s shares saw a positive response, trading 2.96% higher at $5.57 per share during the pre-market session on Monday morning. This strategic partnership highlights the growing demand for innovative medical cannabis products in Canada, with both Aurora and Vectura Fertin Pharma positioned to be key players in this evolving market.
